L-dopa is the most effective drug in the symptomatic management of PD and extends the life span of PD patients.The question whether L-dopa is neurotoxic remains however unresolved. In recent years, increased Homocysteine (Hcy) levels have been observed in L-dopa treated Parkinson's disease (PD) patients, resulting from L-dopa O-methylation by the enzyme catechol-O-methyltransferase. This review summarizes current evidences supporting the possible role of Hcy as mediator of L-dopa toxicity mainly on dopaminergic neurons.
L-dopa related hyperhomocysteinemia: A possible mediator of toxicity?
Defazio G;
2005-01-01
Abstract
L-dopa is the most effective drug in the symptomatic management of PD and extends the life span of PD patients.The question whether L-dopa is neurotoxic remains however unresolved. In recent years, increased Homocysteine (Hcy) levels have been observed in L-dopa treated Parkinson's disease (PD) patients, resulting from L-dopa O-methylation by the enzyme catechol-O-methyltransferase. This review summarizes current evidences supporting the possible role of Hcy as mediator of L-dopa toxicity mainly on dopaminergic neurons.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2005 zoccolella.pdf
Solo gestori archivio
Tipologia:
versione editoriale (VoR)
Dimensione
55.86 kB
Formato
Adobe PDF
|
55.86 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I metadati presenti in IRIS UNICA sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono protetti da diritto d'autore, salvo diversa indicazione.
